A phase 2 trial of fluorouracil (5-FU), cetuximab, bevacizumab (glioblastoma use) and capecitabine in colorectal cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab is a phase 2, interventional study registered as NCT06540326 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 100 participants, started 2024-11-12 and due to reach its primary completion in 2026-04-15. Interventions recorded: irinotecan liposome (II); fluorouracil; cetuximab; bevacizumab; Capecitabine. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Bevacizumab (glioblastoma use), Cetuximab, Fluorouracil (5-FU), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Cetuximab, Fluorouracil (5-FU), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Fluorouracil (5-FU), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Fluorouracil (5-FU), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.